SCHEMBL6750404

SCHEMBL6750404

CC(C)(C)c1cc(C(=O)Cn2c(=N)n(Cc3ccccc3)c3ccccc32)cc(C(=O)O)c1OC(=O)C(F)(F)F

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
F2R P25116 9/20 0.66
MAPT P10636 6/20 0.48
KMT2A Q03164 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
KDM4E B2RXH2 3/20 0.48
MEN1 O00255 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
LMNA P02545 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ALDH1A1 P00352 1/20 0.45
MITF O75030 3/20 0.45
HTT P42858 2/20 0.45
NPSR1 Q6W5P4 3/20 0.45
OXTR P30559 1/20 0.44
AVPR1A P37288 1/20 0.44
BLM P54132 1/20 0.44
TSHR P16473 1/20 0.44
TP53 P04637 2/20 0.43
CXCR3 P49682 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6748424 0.89 F2R (0.64) F2RMAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL6746329 0.86 F2R (0.61) F2RMAPTKMT2ASMN1; SMN2KDM4E
Trifluoroacetic Acid SCHEMBL6750400 0.85 F2R (0.78) F2RMAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL6846941 0.83 F2R (0.78) F2RMAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL6752883 0.83 F2R (0.56) F2RMAPTKMT2ASMN1; SMN2KDM4E
Bromide SCHEMBL6750518 0.82 F2R (0.84) F2RMAPTKMT2ASMN1; SMN2KDM4E
Bromide SCHEMBL6751125 0.82 F2R (0.77) F2RMAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL6750521 0.81 F2R (0.79) F2RMAPTKMT2ASMN1; SMN2KDM4E
Bromide SCHEMBL6752696 0.80 F2R (0.70) F2RMAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL12393183 0.80 F2R (1.00) F2RMAPTKMT2ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040242627-A1 2-Iminoimidazole derivatives (1) EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242627-A1 2-Iminoimidazole derivatives (1) H1-2, H1-0, H1-3 F2R 4027/4885MAPT 4077/4885KMT2A 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.